[go: up one dir, main page]

PL1713473T3 - Kombinacja leków antycholinergicznych i glikokortykoidów do długotrwałego leczenia astmy i POChP - Google Patents

Kombinacja leków antycholinergicznych i glikokortykoidów do długotrwałego leczenia astmy i POChP

Info

Publication number
PL1713473T3
PL1713473T3 PL05706979T PL05706979T PL1713473T3 PL 1713473 T3 PL1713473 T3 PL 1713473T3 PL 05706979 T PL05706979 T PL 05706979T PL 05706979 T PL05706979 T PL 05706979T PL 1713473 T3 PL1713473 T3 PL 1713473T3
Authority
PL
Poland
Prior art keywords
anticholinergics
glucocorticoids
copd
asthma
combination
Prior art date
Application number
PL05706979T
Other languages
English (en)
Inventor
Joachim Goede
Joachim Maus
Peter Jürgen Cnota
Istvan Szelenyi
Original Assignee
Meda Pharma Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meda Pharma Gmbh & Co Kg filed Critical Meda Pharma Gmbh & Co Kg
Publication of PL1713473T3 publication Critical patent/PL1713473T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL05706979T 2004-02-06 2005-01-24 Kombinacja leków antycholinergicznych i glikokortykoidów do długotrwałego leczenia astmy i POChP PL1713473T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54195604P 2004-02-06 2004-02-06
EP05706979A EP1713473B1 (en) 2004-02-06 2005-01-24 The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
PCT/EP2005/000652 WO2005074918A1 (en) 2004-02-06 2005-01-24 The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd

Publications (1)

Publication Number Publication Date
PL1713473T3 true PL1713473T3 (pl) 2013-08-30

Family

ID=34837533

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05706979T PL1713473T3 (pl) 2004-02-06 2005-01-24 Kombinacja leków antycholinergicznych i glikokortykoidów do długotrwałego leczenia astmy i POChP

Country Status (16)

Country Link
US (2) US20050175548A1 (pl)
EP (1) EP1713473B1 (pl)
JP (1) JP4819699B2 (pl)
CN (1) CN100569235C (pl)
AU (1) AU2005210085B2 (pl)
CA (1) CA2551780C (pl)
DK (1) DK1713473T3 (pl)
ES (1) ES2413011T3 (pl)
HR (1) HRP20130460T1 (pl)
NO (1) NO336882B1 (pl)
NZ (1) NZ548300A (pl)
PL (1) PL1713473T3 (pl)
PT (1) PT1713473E (pl)
RU (1) RU2440813C2 (pl)
SI (1) SI1713473T1 (pl)
WO (1) WO2005074918A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
GB0523653D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
NZ568349A (en) * 2005-12-21 2011-05-27 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2009142589A1 (en) * 2008-05-20 2009-11-26 Astrazeneca Ab Combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
TWI792140B (zh) * 2009-05-29 2023-02-11 美商沛爾醫療股份有限公司 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CA2785321C (en) 2009-12-23 2018-08-21 Chiesi Farmaceutici S.P.A. Combination therapy for copd
ES2468835T3 (es) 2009-12-23 2014-06-17 Chiesi Farmaceutici S.P.A. Terapia combinada para EPOC
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
AU2013300009B2 (en) * 2012-08-09 2017-06-15 Chase Pharmaceuticals Corporation Piperidinium quaternary salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
JP6114841B2 (ja) 2013-02-28 2017-04-12 ダーミラ, インク.Dermira, Inc. グリコピロレート塩
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
SI3089735T1 (sl) 2013-12-30 2018-10-30 Chiesi Farmaceutici S.P.A. Sestavek stabilne aerosolne raztopine pod tlakom, ki vsebuje glikopironijev bromid in formoterol
EP4591936A3 (en) 2015-03-23 2025-10-15 Tianli Biotech Pty Ltd Treatment of respiratory diseases
WO2016170518A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
PE20191043A1 (es) 2016-09-19 2019-08-06 Mexichem Fluor Sa De Cv Composicion farmaceutica
RU2691110C2 (ru) * 2017-11-20 2019-06-11 Федеральное государственное бюджетное учреждение науки Сибирский федеральный научный центр агробиотехнологий Российской академии наук (СФНЦА РАН) Препарат для лечения заболеваний дыхательных путей у лошадей и способ его применения
WO2020093098A1 (en) 2018-11-07 2020-05-14 The University Of Melbourne Novel compounds for the treatment of respiratory diseases
CN109498625B (zh) * 2018-12-29 2021-04-16 温州医科大学附属第一医院 一种治疗慢性阻塞性肺疾病的药物组合物及其制备方法
CN114502146A (zh) 2019-12-02 2022-05-13 奇斯药制品公司 用于加压定量吸入器的不锈钢罐
CN120360953B (zh) * 2025-06-24 2025-09-05 成都第一制药有限公司 一种用于copd治疗的莨菪烷类生物碱组合物及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100331255B1 (ko) 1993-07-02 2002-10-25 빅굴덴 롬베르그 케미쉐 화부리크 게엠베하 플루오로알콕시-치환된벤즈아미드및시클릭뉴클레오티드포스포디에스테라아제억제제로서의그의용도
EP0932401A1 (en) * 1996-07-01 1999-08-04 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
WO1999062720A1 (fr) 1998-05-29 1999-12-09 Citizen Watch Co., Ltd. Procede permettant de soumettre une imprimante a jet d'encre a un traitement de pre-utilisation
EP1102579B1 (de) * 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
DK1131059T3 (da) * 1998-11-13 2003-06-30 Jago Res Ag Tørpulver til inhalation
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US6086914A (en) 1999-03-12 2000-07-11 Weinstein; Robert E. Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity
US6203779B1 (en) * 1999-03-19 2001-03-20 Charlie Ricci Methods for treating endoleaks during endovascular repair of abdominal aortic aneurysms
US20040002548A1 (en) 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
DE19961300A1 (de) 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
DE10007203A1 (de) 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009584D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
DE10062712A1 (de) 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
DE50211045D1 (de) * 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
MXPA03010791A (es) 2001-05-25 2004-03-02 Boehringer Ingelheim Pharma Combinacion de inhibidor de pde4 y tiotropio a sus derivados para tratamiento de enfermedades obstructivas de vias respiratorias y de otras enfermedades inflamatorias.
CZ20033150A3 (cs) 2001-05-25 2004-06-16 Pfizer Inc. Inhibitor PDE4 a anticholinergní činidlo v kombinaci pro léčbu obstruktivních chorob dýchacích cest
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
CN1422620A (zh) * 2001-12-07 2003-06-11 中国人民解放军总装备部后勤部军事医学研究所 治疗氮氧化物中毒的气雾剂及其用途和制备方法
US7258118B2 (en) * 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
EP1487411B1 (en) * 2002-03-20 2019-01-02 Civitas Therapeutics, Inc. Inhalable sustained therapeutic formulations
US7084153B2 (en) * 2002-04-12 2006-08-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising steroids and a novel anticholinergic
DE10216429A1 (de) * 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
US20040038958A1 (en) 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
UA82323C2 (uk) 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
WO2004023984A2 (en) 2002-09-13 2004-03-25 Smith C Steven Novel composition and method for treatment of upper respiratory conditions
SI1610787T1 (sl) 2003-03-28 2008-06-30 Nycomed Gmbh Sinergistična kombinacija, ki obsega roflumilastin antiholinergično sredstvo, izbrano izmed tiotropijevih soli, za zdravljenje respiratornih bolezni
US20060189642A1 (en) 2003-03-28 2006-08-24 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
JP2007530917A (ja) * 2003-07-11 2007-11-01 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 改善された周波数決定
DE602005007708D1 (de) 2004-02-06 2008-08-07 Meda Pharma Gmbh & Co Kg Neue kombination von anticholinergen und beta mimetika zur behanldung von atemwegserkrankungen
EP1720577A2 (en) 2004-02-27 2006-11-15 Altana Pharma AG Ciclesonide and glycopyrronium combination
NZ568349A (en) 2005-12-21 2011-05-27 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases

Also Published As

Publication number Publication date
CA2551780A1 (en) 2005-08-18
NO20063879L (no) 2006-11-01
JP2007520508A (ja) 2007-07-26
US20050175548A1 (en) 2005-08-11
CA2551780C (en) 2013-02-26
SI1713473T1 (sl) 2013-06-28
RU2440813C2 (ru) 2012-01-27
DK1713473T3 (da) 2013-06-17
HRP20130460T1 (hr) 2013-06-30
JP4819699B2 (ja) 2011-11-24
WO2005074918A1 (en) 2005-08-18
EP1713473A1 (en) 2006-10-25
US10537550B2 (en) 2020-01-21
ES2413011T3 (es) 2013-07-15
CN100569235C (zh) 2009-12-16
EP1713473B1 (en) 2013-03-13
PT1713473E (pt) 2013-05-13
HK1098356A1 (zh) 2007-07-20
NO336882B1 (no) 2015-11-23
AU2005210085A1 (en) 2005-08-18
US20080300226A1 (en) 2008-12-04
AU2005210085B2 (en) 2010-06-24
RU2006132038A (ru) 2008-03-20
CN1913883A (zh) 2007-02-14
NZ548300A (en) 2010-04-30

Similar Documents

Publication Publication Date Title
SI1713473T1 (sl) Kombinacija antiholinergikov in glukokortikoidov za dolgotranjno zdravljenje astme in KOPB
IL188730A0 (en) Wound dressing and methods of making and using the same
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
IL183840A0 (en) Compositions and methods for reducing the transmissivity of illnesses
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
GB2434983B (en) Methods and compositions for wound healing
GB2441489B (en) Stylet apparatuses and methods of manufacture
IL189364A0 (en) Estrogen compositions and therapeutic methods of use thereof
ZA200704677B (en) Compositions and methods for the treatment of autism
SI1919450T1 (sl) Liposomski sestavek, ki vsebuje antihistaminik in kortikosteroid, in njegova uporaba za izdelavo zdravila za zdravljenje rinitisa in sorodnih motenj
EP1874286A4 (en) METHOD AND COMPOSITIONS FOR TREATING ANXIETY STATE
PL1720408T3 (pl) Mieszaniny i sposoby indukowania odporności w roślinach
GB2421571B (en) Navigation apparatus and program of the same
IL178816A0 (en) The treatment of childhood asthma
EP1729820A4 (en) Impacted Membrane Bond Compounds and Methods of Use Therefor
ZA200703087B (en) Methods and compositions for the treatment of hyperlipidemia
IL189248A0 (en) Use of tiotropium salts in the treatment of severe persistant asthma
EP1937075A4 (en) SYNERGIC COMPOSITION AND METHOD OF USE
EP1945613A4 (en) NOVEL 1-BENZYL-4-PIPERIDINAMINES FOR USE IN THE TREATMENT OF COPD AND ASTHMA
PL1909806T3 (pl) Kompozycja i sposób leczenia objawów astmy
GB0520930D0 (en) Composition and method of use
EP1737475A4 (en) VEGETABLE THERAPY FOR THE TREATMENT OF ASTHMA
GB0403696D0 (en) Process and composition
EP1937242A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES AND ADDITIVES
HK1120038A (en) Novel 1 -benzyl-4-piperidinamines that are useful in the treatment of copd and asthma